These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 8951903)

  • 1. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose 131I.
    Huić D; Medvedec M; Dodig D; Popović S; Ivancević D; Pavlinovic Z; Zuvic M
    Nucl Med Commun; 1996 Oct; 17(10):839-42. PubMed ID: 8951903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants.
    Lassmann M; Luster M; Hänscheid H; Reiners C
    J Nucl Med; 2004 Apr; 45(4):619-25. PubMed ID: 15073258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry.
    Yeung HW; Humm JL; Larson SM
    J Nucl Med; 2000 Jun; 41(6):1082-5. PubMed ID: 10855639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
    J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
    Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants.
    Bajén MT; Mañé S; Muñoz A; García JR
    J Nucl Med; 2000 Dec; 41(12):2038-42. PubMed ID: 11138690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
    Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
    Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
    Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
    Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
    Moser E; Fritsch S; Braun S
    Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study.
    Hoyes KP; Owens SE; Millns MM; Allan E
    Nucl Med Commun; 2004 Mar; 25(3):245-51. PubMed ID: 15094442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic 123I and 131I activities and radioiodine therapy. Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma.
    Meller B; von Hof K; Genina E; Deisting W; Meller J; Richter E; Baehre M
    Nuklearmedizin; 2005; 44(6):243-8. PubMed ID: 16400384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake.
    Chopra S; Wastie ML; Chan S; Vincent RM; Przeslak A; Perkins AC; Ubhi CS
    Nucl Med Commun; 1996 Aug; 17(8):687-91. PubMed ID: 8878128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
    Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
    Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed dosage of 131I for remnant ablation in patients with differentiated thyroid carcinoma without pre-ablative diagnostic 131I scintigraphy.
    de Klerk JM; de Keizer B; Zelissen PM; Lips CM; Koppeschaar HP
    Nucl Med Commun; 2000 Jun; 21(6):529-32. PubMed ID: 10894561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
    Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
    Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.